Prevention of type 2 diabetes

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Type 2 diabetes is a major cause of morbidity and mortality resulting from its microangiopathic and macroangiopathic complications. Current approaches to its management and to the prevention of diabetic complications are difficult to implement effectively, and there is little evidence to date that these approaches are reducing the impact of this disease. The recognition that type 2 diabetes usually has a prolonged prediabetic phase raises the possibility that the emergence of hyperglycemia and the atherosclerotic complications associated with diabetes may be preventable by the institution of early treatment modalities. Sufficient data suggest that life-style modification or pharmacotherapy directed at improving insulin sensitivity or insulin secretion in subjects with impaired glucose tolerance may reduce progression to diabetes. Two long-term prospective, controlled trials have been initiated to test this hypothesis.

Original languageEnglish
Pages (from-to)805-821
Number of pages17
JournalMedical Clinics of North America
Volume82
Issue number4
DOIs
StatePublished - Aug 8 1998

Fingerprint

Type 2 Diabetes Mellitus
Glucose Intolerance
Diabetes Complications
Hyperglycemia
Insulin Resistance
Life Style
Insulin
Morbidity
Drug Therapy
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevention of type 2 diabetes. / Goldberg, Ronald B.

In: Medical Clinics of North America, Vol. 82, No. 4, 08.08.1998, p. 805-821.

Research output: Contribution to journalArticle

@article{c9e822dd86f74a06b3f9056132a263d7,
title = "Prevention of type 2 diabetes",
abstract = "Type 2 diabetes is a major cause of morbidity and mortality resulting from its microangiopathic and macroangiopathic complications. Current approaches to its management and to the prevention of diabetic complications are difficult to implement effectively, and there is little evidence to date that these approaches are reducing the impact of this disease. The recognition that type 2 diabetes usually has a prolonged prediabetic phase raises the possibility that the emergence of hyperglycemia and the atherosclerotic complications associated with diabetes may be preventable by the institution of early treatment modalities. Sufficient data suggest that life-style modification or pharmacotherapy directed at improving insulin sensitivity or insulin secretion in subjects with impaired glucose tolerance may reduce progression to diabetes. Two long-term prospective, controlled trials have been initiated to test this hypothesis.",
author = "Goldberg, {Ronald B}",
year = "1998",
month = "8",
day = "8",
doi = "10.1016/S0025-7125(05)70025-0",
language = "English",
volume = "82",
pages = "805--821",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Prevention of type 2 diabetes

AU - Goldberg, Ronald B

PY - 1998/8/8

Y1 - 1998/8/8

N2 - Type 2 diabetes is a major cause of morbidity and mortality resulting from its microangiopathic and macroangiopathic complications. Current approaches to its management and to the prevention of diabetic complications are difficult to implement effectively, and there is little evidence to date that these approaches are reducing the impact of this disease. The recognition that type 2 diabetes usually has a prolonged prediabetic phase raises the possibility that the emergence of hyperglycemia and the atherosclerotic complications associated with diabetes may be preventable by the institution of early treatment modalities. Sufficient data suggest that life-style modification or pharmacotherapy directed at improving insulin sensitivity or insulin secretion in subjects with impaired glucose tolerance may reduce progression to diabetes. Two long-term prospective, controlled trials have been initiated to test this hypothesis.

AB - Type 2 diabetes is a major cause of morbidity and mortality resulting from its microangiopathic and macroangiopathic complications. Current approaches to its management and to the prevention of diabetic complications are difficult to implement effectively, and there is little evidence to date that these approaches are reducing the impact of this disease. The recognition that type 2 diabetes usually has a prolonged prediabetic phase raises the possibility that the emergence of hyperglycemia and the atherosclerotic complications associated with diabetes may be preventable by the institution of early treatment modalities. Sufficient data suggest that life-style modification or pharmacotherapy directed at improving insulin sensitivity or insulin secretion in subjects with impaired glucose tolerance may reduce progression to diabetes. Two long-term prospective, controlled trials have been initiated to test this hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=0031855799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031855799&partnerID=8YFLogxK

U2 - 10.1016/S0025-7125(05)70025-0

DO - 10.1016/S0025-7125(05)70025-0

M3 - Article

C2 - 9706122

AN - SCOPUS:0031855799

VL - 82

SP - 805

EP - 821

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 4

ER -